Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03264664 · ClinicalTrials.gov registry record · Phase 1
Study of E7386 in Participants With Selected Advanced Neoplasms
A Phase 1 study of Advanced Neoplasms, sponsored by Eisai.
- Active
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 10
- Study locations
NCT03264664 is a Phase 1 study of Advanced Neoplasms that is active but no longer recruiting, run by Eisai. The registered enrollment target is 60 participants. The trial reports 10 study locations across 8 states.
The verdict
NCT03264664, a Phase 1 study of Advanced Neoplasms, is active but no longer recruiting, sponsored by Eisai.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 10
- Study locations
Study Summary
This study will be conducted to assess the safety/tolerability profile of E7386 as a single agent administered orally in participants with selected advanced or recurrent neoplasms and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of E7386.
Conditions Studied
Interventions
- DRUG E7386
Study Locations (10)
California
- USC Norris Comprehensive Cancer Center - Los Angeles
- California Liver Research Institute - Pasadena
Other
- Royal Free London NHS Foundation Trust, Royal Free Hospital - London
- Imperial College Healthcare NHS Trust - London
Arizona
- Mayo Clinic Comprehensive Caner - Phoenix
Florida
- Mayo Clinic Comprehensive Cancer - Jacksonville
Minnesota
- Mayo Clinic Comprehensive Caner - Rochester
Lanarkshire
- The Beatson West of Scotland Cancer Centre - Glasgow
Lancashire
- The Christie NHS Foundation Trust - Manchester
Surrey
- Royal Marsden Hospital NHS Foundation Trust - Sutton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-07-27 |
| Est. Completion | 2027-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03264664
The ClinicalTrials.gov registry entry for NCT03264664 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which E7386 is the first listed.
NCT03264664 reports 10 study locations spanning 8 distinct geographic areas - top geographies include California, Other, Arizona.
Frequently Asked Questions
What is clinical trial NCT03264664 about?
NCT03264664 is a clinical study titled "Study of E7386 in Participants With Selected Advanced Neoplasms". This study will be conducted to assess the safety/tolerability profile of E7386 as a single agent administered orally in participants with selected advanced or recurrent neoplasms and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of E7386.
What is the current status of trial NCT03264664?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2017-07-27. Estimated completion is 2027-03-31.
What conditions does trial NCT03264664 study?
This clinical trial studies the following conditions: Advanced Neoplasms.
What interventions are being tested in trial NCT03264664?
The interventions under investigation include: E7386 (DRUG).
Who is sponsoring clinical trial NCT03264664?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03264664 being conducted?
This trial has 10 study locations across Arizona, California, Florida, Minnesota, Lanarkshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.